Remove Atherosclerosis Remove Innovation Remove Plaque
article thumbnail

Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis

Frontiers in Cardiovascular Medicine

In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques.

article thumbnail

Roche's Lp(a) Gen.2 Molarity Assay Receives FDA Clearance

DAIC

Roche has an unrivaled ability to provide access to testing at scale and is committed to advancing innovation in preventive cardiology. More than 90% of the Lp(a) level is influenced by variations in the genes controlling the Lp(a) particle production, 2 in which lifestyle interventions such as diet and exercise have no significant impact.

article thumbnail

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

DAIC

Previous to GWU, Earls served as Medical Director and Vice President at Fairfax Radiological Consultants (FRC) in Fairfax, VA, where he was an early innovator and clinical adopter of coronary CT angiography. With Plaque Features Associated with False Positives. 25, 2024 in the European Heart Journal Cardiovascular Imaging 1.

article thumbnail

Coronary Artery Calcification: Current Concepts and Clinical Implications

Circulation

Coronary artery calcification (CAC) accompanies the development of advanced atherosclerosis. Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood. Circulation, Volume 149, Issue 3 , Page 251-266, January 16, 2024.

article thumbnail

Trial Results: Low-Dose Colchicine HelpsTreat Cardiovascular Disease

DAIC

The study, Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial, was presented at the American College of Cardiology 74th Annual Scientific Session and Expo ( ACC.25 mg on atherosclerotic plaque. Budoff, M.D.,

article thumbnail

Trial Results: Low-Dose Colchicine Helps Treat Cardiovascular Disease

DAIC

The study, Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial, was presented at the American College of Cardiology 74th Annual Scientific Session and Expo ( ACC.25 mg on atherosclerotic plaque. Budoff, M.D.,

article thumbnail

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

DAIC

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 101272, [link].